Considering the use of GLP-1 receptor agonists in women with obesity prior to pregnancy: a narrative review

Archives of Gynecology and Obstetrics, Journal Year: 2025, Volume and Issue: 311(5), P. 1241 - 1247

Published: Jan. 7, 2025

Abstract Purpose Metabolic disease, including obesity and type 2 diabetes, are amongst the most significant health issues facing women of reproductive age. To date, no antenatal weight management tools have reduced risk adverse outcomes for with their offspring, resulting in a shift focus to pre-conception period. Although not yet recognised international guidelines, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) being increasingly used prior conception. Methods A literature search PubMed, Medline, Embase databases identified relevant articles describing use GLP-1 RAs during pregnancy. Papers were selected based on relevance originality, clinical trials, large observational studies meta-analyses preferentially included. Results This narrative review summarises mechanism action effects observed non-pregnant adults. It synthesises available data from human animal regarding safety efficacy pregnancy, consequences inadvertent drug exposure early In considering need balance risks metabolic disease posed by exposure, it highlights areas where further research is needed guide decision-making. Conclusion may role facilitating loss improving However, there currently insufficient evidence demonstrate that this class drugs pregnancy improves outcomes.

Language: Английский

---

Role of Glucagon-Like Peptide-1 Receptor Agonists in People With Infertility and Pregnancy

Obstetrics and Gynecology, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 23, 2025

Obesity is a chronic condition that causes significant morbidity and mortality in people the United States around world. Traditional means of weight loss include diet, exercise, behavioral modifications, surgery. New medications, glucagon-like peptide-1 receptor agonists, are revolutionizing management but have implications for fertility pregnancy. associated with infertility may affect response to ovulation induction medications. In pregnancy, obesity increases risks spontaneous abortion, birth defects, gestational diabetes, hypertensive disorders cesarean delivery, stillbirth. Lifestyle changes alone not improved outcomes. Glucagon-like agonists new medications targeting gut hormones can help achieve their goals contraindicated Obstetrician-gynecologists should work patients manage these before they become pregnant, between pregnancies, after delivery.

Language: Английский

---

Weight Reduction with GLP-1 Agonists and Paths for Discontinuation While Maintaining Weight Loss

Biomolecules, Journal Year: 2025, Volume and Issue: 15(3), P. 408 - 408

Published: March 13, 2025

Worldwide, nearly 40% of adults are overweight and 13% obese. Health consequences excess weight include cardiovascular diseases, type 2 diabetes, dyslipidemia, increased mortality. Treating obesity is challenging calorie restriction often leads to rebound gain. Treatments such as bariatric surgery create hesitancy among patients due their invasiveness. GLP-1 medications have revolutionized loss can reduce body in obese by between 15% 25% on average after about 1 year. Their mode action mimic the endogenous GLP-1, an intestinal hormone that regulates glucose metabolism satiety. However, drugs carry known risks and, since use for recent, may unforeseen well. They a boxed warning people with personal or family history medullary thyroid carcinoma multiple endocrine neoplasia syndrome 2. Gastrointestinal adverse events (nausea, vomiting, diarrhea) fairly common while pancreatitis obstruction rarer. There be lean mass well premature facial aging. A significant disadvantage using these high rate regain when they discontinued. Achieving success pharmacologic treatment then weaning avoid future negative effects would ideal.

Language: Английский

---

Exploring the Immunological Aspects and Treatments of Recurrent Pregnancy Loss and Recurrent Implantation Failure

International Journal of Molecular Sciences, Journal Year: 2025, Volume and Issue: 26(3), P. 1295 - 1295

Published: Feb. 3, 2025

Recurrent pregnancy loss (RPL) is defined as the occurrence of two or more consecutive losses before 24 weeks gestation. It affects 3-5% women who are attempting to conceive. RPL can stem from a variety causes and frequently associated with psychological distress diminished quality life. By contrast, recurrent implantation failure (RIF) refers inability achieve successful after three high-quality embryo transfers at least instances egg donation. RIF shares several causative factors RPL. The immunological underpinnings these conditions involve alterations in uterine NK cells, reductions M2 macrophages myeloid-derived suppressor an increased Th1/Th2 ratio, decreased Treg/Th17 presence shared ≥3 HLA alleles between partners, autoimmune disorders. Various therapeutic approaches have been employed address concerns, achieving varying degrees success, although some therapies remain contentious within medical community. This review intends explore implicated analyze treatments for conditions, which may include steroids, intravenous immunoglobulins, calcineurin inhibitors, anti-TNF antibodies, intralipid infusions, granulocyte colony-stimulating factor, lymphocyte immunotherapy.

Language: Английский

---

Recommendations of the Spanish Society of Endocrinology and Nutrition (SEEN) on “what not to do” in clinical practice

Endocrinología Diabetes y Nutrición (English ed ), Journal Year: 2025, Volume and Issue: unknown, P. 101531 - 101531

Published: March 1, 2025

Language: Английский

---

Effects of Obesity on Female Fertility: Mechanisms, Clinical Consequences and Management Strategies

Advances in Clinical Medicine, Journal Year: 2025, Volume and Issue: 15(03), P. 1646 - 1653

Published: Jan. 1, 2025

Language: Английский

---

The use of GLP-1: receptor agonist medications for benign gynecology

Current Opinion in Obstetrics & Gynecology, Journal Year: 2025, Volume and Issue: unknown

Published: April 4, 2025

Purpose of review This summarizes research on glucagon-like peptide-1 receptor agonist (GLP-1 RA) medications and their relevance in the treatment benign gynecologic conditions. Recent findings GLP-1 RA use is increasing popularity USA, with expanding applications for gynecology. may improve weight loss, metabolic dysfunction, menstrual regularity patients polycystic ovarian syndrome (PCOS). Side effects these medications, including delayed gastric emptying, impact perioperative management, efficacy oral contraception tirzepatide. Research ongoing infertility endometrial hyperplasia treatment. studies showed a higher spontaneous conception rate pregnancy combined metformin therapy when taken before IVF. Further are needed to establish recommendations medication treating Summary With obesity, diabetes, cardiovascular disease rise also increasing. RAs currently indicated diabetes glycemic control, addition loss management. Gynecologists must consider implications disorders, such as PCOS, contraceptive care, potential impacts hyperplasia.

Language: Английский

---

Teratogenic risks of treated and untreated maternal obesity

Seminars in Perinatology, Journal Year: 2025, Volume and Issue: unknown, P. 152081 - 152081

Published: April 1, 2025

Language: Английский

---

Eine neue Ära der Diabetestherapie – Komorbiditäten im Fokus!

Gefässchirurgie, Journal Year: 2025, Volume and Issue: unknown

Published: April 28, 2025

---

Glucagon‐like peptide 1 (GLP‐1) receptor agonists' use during pregnancy: Safety data from regulatory clinical trials

Diabetes Obesity and Metabolism, Journal Year: 2025, Volume and Issue: unknown

Published: May 6, 2025

Abstract Aims The prevalence of diabetes and obesity continues to rise in women reproductive age, with significant implications for both mother foetus. Glucagon‐like peptide‐1 receptor agonists are effective treatments obesity. However, no currently approved use during pregnancy. We describe the outcomes unplanned pregnancies regulatory clinical trials submitted Food Drug Administration European Medicines Agency. Materials Methods A search was conducted documentation published by Agency on agonists. Clinical Medical Reviews Center Evaluation Research at every agonist prior market authorisation were assessed gather information that occurred while females partaking development programmes such drugs. Results Evidence having planned is lacking, only evidence thus far relies occurring inadvertently trials. incidence congenital abnormalities humans appears relatively low following Conclusions Key knowledge gaps must be addressed before introduction class drugs pregnant women. Currently, should stopped as soon patient becomes aware a establishment registries designed capture data relating cases exposure pregnancy high priority, where already exist, findings need published.

Language: Английский

---